SEQUENT SCIENTIFIC
Quarterly Results Analysis [Sep2024]
SEQUENT SCIENTIFIC Quarterly Results
Consolidated | Sep2024 UnAudited |
Jun2024 UnAudited |
Mar2024 UnAudited |
Dec2023 UnAudited |
Sep2023 UnAudited |
Jun2023 UnAudited |
Mar2023 Audited |
Dec2022 UnAudited |
---|---|---|---|---|---|---|---|---|
Revenues | ₹369 Cr | ₹390 Cr | ₹361 Cr | ₹329 Cr | ₹346 Cr | ₹333 Cr | ₹367 Cr | ₹375 Cr |
Expenses | ₹330 Cr | ₹348 Cr | ₹329 Cr | ₹307 Cr | ₹331 Cr | ₹341 Cr | ₹370 Cr | ₹365 Cr |
Operating Income | ₹39 Cr | ₹42 Cr | ₹32 Cr | ₹22 Cr | ₹15 Cr | ₹-8 Cr | ₹-3 Cr | ₹10 Cr |
Other Income | ₹5 Cr | ₹3 Cr | ₹4 Cr | ₹5 Cr | ₹2 Cr | ₹1 Cr | ₹2 Cr | ₹3 Cr |
Interest | ₹14 Cr | ₹16 Cr | ₹12 Cr | ₹13 Cr | ₹13 Cr | ₹10 Cr | ₹11 Cr | ₹10 Cr |
Depreciation | ₹17 Cr | ₹16 Cr | ₹16 Cr | ₹15 Cr | ₹15 Cr | ₹14 Cr | ₹15 Cr | ₹14 Cr |
Profit Before Tax | ₹8 Cr | ₹12 Cr | ₹3 Cr | ₹1 Cr | ₹-3 Cr | ₹-56 Cr | ₹-89 Cr | ₹-10 Cr |
Profit After Tax | ₹6 Cr | ₹9 Cr | ₹1 Cr | ₹11 Cr | ₹-7 Cr | ₹-35 Cr | ₹-92 Cr | ₹-10 Cr |
EPS | ₹0.10 | ₹0.26 | ₹-0.04 | ₹0.33 | ₹-0.34 | ₹-1.40 | ₹-0.04 | ₹-0.36 |
Industry Peers & Returns | 1W | 1M | 1Y |
SEQUENT SCIENTIFIC | -7.7% | -7.1% | 26.4% |
SUN PHARMACEUTICAL INDUSTRIES | 1.4% | -4.1% | 32.1% |
CIPLA | -2.2% | -7.3% | 0.2% |
DR REDDYS LABORATORIES | -7.1% | -13.8% | 8% |
ZYDUS LIFESCIENCES | -6.4% | -5.2% | 31.2% |
DIVIS LABORATORIES | -4.2% | -5.1% | 59.6% |
MANKIND PHARMA | -4.1% | -14.4% | 17% |
TORRENT PHARMACEUTICALS | 5.6% | -2.1% | 30.3% |
LUPIN | -1.2% | -6.7% | 48.2% |
SEQUENT SCIENTIFIC Quarterly Revenues
Revenues | |
---|---|
Q-o-Q | -5.53 % |
Y-o-Y | 6.56 % |
Quarters | Revenues | % Change | |
---|---|---|---|
Sep2024 | ₹369 Cr | -5.53 | |
Jun2024 | ₹390 Cr | 8.03 | |
Mar2024 | ₹361 Cr | 9.67 | |
Dec2023 | ₹329 Cr | -4.80 | |
Sep2023 | ₹346 Cr | 3.83 | |
Jun2023 | ₹333 Cr | -9.12 | |
Mar2023 | ₹367 Cr | -2.30 | |
Dec2022 | ₹375 Cr | - |
SEQUENT SCIENTIFIC Quarterly Operating Profit
Operating Profit | |
---|---|
Q-o-Q | -6.79 % |
Y-o-Y | 158.43 % |
Quarters | Operating Profit | % Change | |
---|---|---|---|
Sep2024 | ₹39 Cr | -6.79 | |
Jun2024 | ₹42 Cr | 30.00 | |
Mar2024 | ₹32 Cr | 45.04 | |
Dec2023 | ₹22 Cr | 47.05 | |
Sep2023 | ₹15 Cr | Positive | |
Jun2023 | ₹-8 Cr | Negative | |
Mar2023 | ₹-3 Cr | Negative | |
Dec2022 | ₹10 Cr | - |
Operating Margins | |
---|---|
Q-o-Q | -1.30 % |
Y-o-Y | 142.79 % |
Quarters | Operating Margin% | % Change | |
---|---|---|---|
Sep2024 | 10.61% | -1.30 | |
Jun2024 | 10.75% | 20.38 | |
Mar2024 | 8.93% | 32.10 | |
Dec2023 | 6.76% | 54.69 | |
Sep2023 | 4.37% | Positive | |
Jun2023 | -2.47% | Negative | |
Mar2023 | -0.92% | Negative | |
Dec2022 | 2.75% | - |
SEQUENT SCIENTIFIC Quarterly Profit After Tax
Profit After Tax(PAT) | |
---|---|
Q-o-Q | -30.02 % |
Y-o-Y | Positive |
Quarters | Profit After Tax | % Change | |
---|---|---|---|
Sep2024 | ₹6 Cr | -30.02 | |
Jun2024 | ₹9 Cr | 611.15 | |
Mar2024 | ₹1 Cr | -88.07 | |
Dec2023 | ₹11 Cr | Positive | |
Sep2023 | ₹-7 Cr | Negative | |
Jun2023 | ₹-35 Cr | Negative | |
Mar2023 | ₹-92 Cr | Negative | |
Dec2022 | ₹-10 Cr | - |
PAT Margins | |
---|---|
Q-o-Q | -25.86 % |
Y-o-Y | Positive |
Quarters | PAT Margin(%) | % Change | |
---|---|---|---|
Sep2024 | 1.72 % | -25.86 | |
Jun2024 | 2.32 % | 562.86 | |
Mar2024 | 0.35 % | -89.20 | |
Dec2023 | 3.24 % | Positive | |
Sep2023 | -1.99 % | Negative | |
Jun2023 | -10.41 % | Negative | |
Mar2023 | -25.21 % | Negative | |
Dec2022 | -2.61 % | - |
SEQUENT SCIENTIFIC Quarterly Earnings Per Share (EPS)
EPS | |
---|---|
Q-o-Q | -61.54 % |
Y-o-Y | Positive |
Quarters | EPS | % Change | |
---|---|---|---|
Sep2024 | ₹0.1 | -61.54 | |
Jun2024 | ₹0.26 | Positive | |
Mar2024 | ₹-0.04 | Negative | |
Dec2023 | ₹0.33 | Positive | |
Sep2023 | ₹-0.34 | Negative | |
Jun2023 | ₹-1.4 | Negative | |
Mar2023 | ₹-0.04 | Negative | |
Dec2022 | ₹-0.36 | - |
You may also like the below Video Courses
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs MANKIND PHARMA LTD